Mike has served as a member of Nanocopoeia’s board of directors since 2011.
With more than 20 years of industry experience developing and commercializing numerous pharmaceutical drug products and creating significant business value, he continues to oversee that Nanocopoeia’s business value is maximized.
Prior to Nanocopoeia, Mike was President and Chief Executive Officer of Paddock Laboratories, a developer, manufacturer and marketer of OTC and specialty brand and generic prescription products. In less than three years, Mike grew sales from $65 million to over $220 million and successfully completed acquisition transaction to Perrigo for $540 million. Prior to Paddock Laboratories, Mike held multiple leadership positions including President, Par Pharmaceutical Generics Division (1998 – 2006). He has also held executive positions at two of the country’s largest pharmaceutical distributors. Mike is Chairman of the Board of Directors for Eagle Pharmaceuticals, and member of the board of directors of RiboCor, Inc.